Additionally, in a recent publication, Singh et al. [186] highlighted the importance of lncRNA H19 and its association with NEPC, suggesting that upregulated H19 levels can be used as a candidate diagnostic and predictive marker of NEPC and a putative marker of biochemical recurrence and metastatic disease in patients receiving ADT. This evidence concerns the gene H19 and metastatic neoplasm.